De Rosa R, et al. - The safety and efficacy of everolimus-eluting bioresorbable vascular scaffold (BRS) vs everolimus-eluting metallic stents (EES) was assessed in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). Researchers analyzed data from the relevant clinical studies. EES vs BRS offered increased risk of definite scaffold thrombosis and target lesion revascularization (TLR) at mid-term follow-up. When TLR due to device thrombosis were excluded, the difference in risk estimates between the 2 groups decreased considerably and was no longer significant.